Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: LYM040
MIFTS: 54

Lymphoblastic Lymphoma

Categories: Blood diseases, Cancer diseases, Immune diseases, Rare diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Lymphoblastic Lymphoma

About this section

MalaCards integrated aliases for Lymphoblastic Lymphoma:

Name: Lymphoblastic Lymphoma 12 74 52 15 37
Precursor Cell Lymphoblastic Leukemia Lymphoma 71
Precursor Cell Lymphoblastic Lymphoma 71
Lymphoma, Lymphoblastic 52
Lymphoma Lymphoblastic 54

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Immune diseases Blood diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

Disease Ontology 12 DOID:0080147
ICD10 32 C83.5
UMLS 71 C0079748 C1961102
Sources

Summaries for Lymphoblastic Lymphoma

About this section
Disease Ontology : 12 A lymphoma that has material basis in immature malignant lymphocytes (lymphoblasts) committed to the B-cell or T-cell lineage and located in primarily lymph nodes or located in extranodal sites.

MalaCards based summary : Lymphoblastic Lymphoma, also known as precursor cell lymphoblastic leukemia lymphoma, is related to b-lymphoblastic leukemia/lymphoma and t-cell acute lymphoblastic leukemia. An important gene associated with Lymphoblastic Lymphoma is DNTT (DNA Nucleotidylexotransferase), and among its related pathways/superpathways are Transcriptional misregulation in cancer and NF-kappaB Signaling. The drugs Teniposide and Methylphenidate have been mentioned in the context of this disorder. Affiliated tissues include primarily lymph nodes, extranodal sites and t cells, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 74 Acute lymphoblastic leukemia (ALL) is a cancer of the lymphoid line of blood cells characterized by the... more...

Sources

Related Diseases for Lymphoblastic Lymphoma

About this section

Diseases related to Lymphoblastic Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 334)
# Related Disease Score Top Affiliating Genes
1 b-lymphoblastic leukemia/lymphoma 33.2 ZMYM2 MYC FGFR1
2 t-cell acute lymphoblastic leukemia 32.5 TAL1 RAG1 PTPRC NOTCH1 MYC LMO2
3 leukemia, acute lymphoblastic 31.0 TAL1 RAG1 PTPRC NOTCH1 MYC MPO
4 ovarian lymphoma 30.7 MME BCL6
5 myeloproliferative neoplasm 30.6 ZMYM2 MPO KMT2A FGFR1 CEP85L
6 thymoma 30.5 PTPRC NOTCH1 DNTT CD5
7 lymphosarcoma 30.5 TNFRSF8 PTPRC BCL6
8 myeloid sarcoma 30.5 PTPRC MPO KMT2A DNTT
9 leukemia, acute lymphoblastic 3 30.4 MPO MME KMT2A DNTT CDKN2B
10 burkitt lymphoma 30.3 TNFRSF8 MYC MME DNTT CDKN2B BCL6
11 leukemia 30.3 TAL1 NOTCH1 MYC MME LMO2 KMT2A
12 follicular lymphoma 30.2 MYC MME CD5 BCL6
13 pediatric lymphoma 30.2 TNFRSF8 MYC MME BCL6
14 angioimmunoblastic t-cell lymphoma 30.2 TNFRSF8 MME BCL6
15 acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) 30.1 MPO KMT2A DNTT
16 dendritic cell tumor 30.1 PTPRC MPO DNTT
17 precursor t-cell acute lymphoblastic leukemia 30.1 TAL1 NOTCH1 MYC MPO LMO2 KMT2A
18 acute leukemia 30.1 TAL1 NOTCH1 MPO KMT2A DNTT CDKN2B
19 childhood leukemia 30.0 MPO KMT2A CDKN2B
20 lymphoma 29.9 ZMYM2 TNFRSF8 TAL1 PTPRC NOTCH1 MYC
21 mixed phenotype acute leukemia 29.9 MPO KMT2A FGFR1 DNTT CD7
22 t-cell lymphoma, subcutaneous panniculitis-like 29.9 TNFRSF8 CD7
23 b-cell lymphoma 29.9 TNFRSF8 PTPRC MYC MME CDKN2B CD5
24 peripheral t-cell lymphoma 29.9 TNFRSF8 PTPRC NOTCH1 MME CD5 BCL6
25 t-cell adult acute lymphocytic leukemia 29.9 TNFRSF8 CD7 CD5
26 myelodysplastic syndrome 29.8 NOTCH1 MYC MPO KMT2A DNTT CDKN2B
27 pancytopenia 29.7 PTPRC MPO KMT2A CD7 CD5
28 ewing sarcoma 29.7 TNFRSF8 PTPRC MYC FLI1 FGFR1 DNTT
29 mantle cell lymphoma 29.6 PTPRC NOTCH1 MYC MME CDKN2B CD5
30 adult acute lymphocytic leukemia 29.6 TNFRSF8 MME CDKN2B CD7 CD5
31 plasma cell neoplasm 29.6 PTPRC MYC MME CD5 BCL6
32 diffuse large b-cell lymphoma 29.5 TNFRSF8 PTPRC MYC MME LMO2 CD5
33 composite lymphoma 29.5 TNFRSF8 MME CD5 BCL6
34 leukemia, chronic myeloid 29.5 TAL1 PTPRC MYC MPO KMT2A FGFR1
35 t-cell lymphoblastic leukemia/lymphoma 29.4 TNFRSF8 TAL1 RAG1 PTPRC NOTCH1 MYC
36 myeloma, multiple 29.1 TNFRSF8 PTPRC NOTCH1 MYC MME CD5
37 immune deficiency disease 29.1 TNFRSF8 RAG1 PTPRC CD5 BCL6
38 acute promyelocytic leukemia 29.0 PTPRC NOTCH1 MYC MPO KMT2A CDKN2B
39 leukemia, chronic lymphocytic 28.4 TNFRSF8 PTPRC NOTCH1 MYC MME KMT2A
40 lymphoma, non-hodgkin, familial 28.3 ZMYM2 TNFRSF8 TAL1 RAG1 PTPRC NOTCH1
41 hematologic cancer 28.2 TNFRSF8 PTPRC NOTCH1 MYC MME KMT2A
42 leukemia, acute myeloid 27.9 TNFRSF8 TAL1 PTPRC NOTCH1 MYC MPO
43 t-cell childhood lymphoblastic lymphoma 12.6
44 chromosome 8p11 myeloproliferative syndrome 11.7
45 childhood t-cell acute lymphoblastic leukemia 11.6
46 pdgfra-associated chronic eosinophilic leukemia 11.3
47 refractory t lymphoblastic leukemia/lymphoma 11.3
48 myeloid and lymphoid neoplasms with eosinophilia and abnormalities of pdgfra, pdgfrb, and fgfr1 10.6 ZMYM2 FGFR1
49 lymphoma, hodgkin, classic 10.6
50 high grade b-cell lymphoma with myc and/ or bcl2 and/or bcl6 rearrangement 10.5 MYC BCL6

Graphical network of the top 20 diseases related to Lymphoblastic Lymphoma:



Diseases related to Lymphoblastic Lymphoma
Sources

Symptoms & Phenotypes for Lymphoblastic Lymphoma

About this section

GenomeRNAi Phenotypes related to Lymphoblastic Lymphoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00106-A-0 9.93 PTPRC
2 Decreased viability GR00221-A-1 9.93 FGFR1 MYC
3 Decreased viability GR00221-A-2 9.93 FGFR1
4 Decreased viability GR00221-A-3 9.93 MYC
5 Decreased viability GR00249-S 9.93 MYC
6 Decreased viability GR00386-A-1 9.93 CD5 FGFR1 NOTCH1
7 Decreased viability GR00402-S-2 9.93 KMT2A MYC TNFRSF8
8 Reduced mammosphere formation GR00396-S 9.28 BCL6 CD5 CD7 KMT2A LMO2 MYC
9 Increased the percentage of infected cells GR00402-S-1 8.65 CD99

MGI Mouse Phenotypes related to Lymphoblastic Lymphoma:

45 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 immune system MP:0005387 10.39 BCL6 CD5 CD7 CDKN2B DNTT FGFR1
2 hematopoietic system MP:0005397 10.38 BCL6 CD5 CD7 CDKN2B DNTT FGFR1
3 cellular MP:0005384 10.29 BCL6 CDKN2B FGFR1 FLI1 KMT2A LMO2
4 cardiovascular system MP:0005385 10.26 BCL6 FGFR1 FLI1 KMT2A LMO2 MPO
5 integument MP:0010771 10.21 BCL6 CD5 CDKN2B FGFR1 KMT2A LMO2
6 endocrine/exocrine gland MP:0005379 10.19 BCL6 CD7 CDKN2B FGFR1 FLI1 MYC
7 mortality/aging MP:0010768 10.18 BCL6 CDKN2B FGFR1 FLI1 KMT2A LMO2
8 liver/biliary system MP:0005370 10.06 BCL6 FLI1 KMT2A LMO2 MME MYC
9 nervous system MP:0003631 10 CD5 FGFR1 FLI1 KMT2A LMO2 MME
10 neoplasm MP:0002006 9.92 CDKN2B FLI1 KMT2A LMO2 MYC NOTCH1
11 no phenotypic analysis MP:0003012 9.7 BCL6 CD5 CDKN2B FGFR1 KMT2A MYC
12 normal MP:0002873 9.61 BCL6 CD5 DNTT FGFR1 KMT2A MYC
13 renal/urinary system MP:0005367 9.23 CDKN2B FGFR1 KMT2A LMO2 NOTCH1 PTPRC
Sources

Drugs & Therapeutics for Lymphoblastic Lymphoma

About this section

Drugs for Lymphoblastic Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 499)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Teniposide Approved Phase 4 29767-20-2 34698
2
Methylphenidate Approved, Investigational Phase 4 113-45-1 4158
3
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
4
Micafungin Approved, Investigational Phase 4 235114-32-6 477468 3081921
5
Posaconazole Approved, Investigational, Vet_approved Phase 4 171228-49-2 147912
6
Epirubicin Approved Phase 4 56420-45-2 41867
7
Nicotine Approved Phase 4 54-11-5 942 89594
8
Amphotericin B Approved, Investigational Phase 4 1397-89-3 5280965 14956
9
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
10
Ergocalciferol Approved, Nutraceutical Phase 4 50-14-6 5280793
11
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 5280795 6221
12
Calcifediol Approved, Nutraceutical Phase 4 19356-17-3 5283731 6433735
13
Ethylene Phase 4 74-85-1 6325
14 Dopamine Agents Phase 4
15 HH-GV-678 Phase 4
16 Heptavalent Pneumococcal Conjugate Vaccine Phase 4
17 Calciferol Phase 4
18 Ergocalciferols Phase 4
19 Hydroxycholecalciferols Phase 4
20 Vitamin D2 Phase 4
21 Amebicides Phase 4
22 Liposomal amphotericin B Phase 4
23 Orange Approved Phase 3
24
Cefepime Approved, Investigational Phase 3 88040-23-7 5479537
25
Lorazepam Approved Phase 3 846-49-1 3958
26
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
27
Morphine Approved, Investigational Phase 3 57-27-2 5288826
28
Dactinomycin Approved, Investigational Phase 3 50-76-0 457193 2019
29
Cobalt Approved, Experimental Phase 3 7440-48-4 104729
30
Iron Approved, Experimental Phase 3 15438-31-0, 7439-89-6 27284 23925
31
Calcium carbonate Approved, Investigational Phase 3 471-34-1
32
Guaifenesin Approved, Investigational, Vet_approved Phase 3 93-14-1 3516
33
Erythromycin Approved, Investigational, Vet_approved Phase 2, Phase 3 114-07-8 12560 441411
34
Chlorhexidine Approved, Vet_approved Phase 3 55-56-1 9552079 2713
35
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
36
Ofloxacin Approved Phase 3 82419-36-1 4583
37
Carvedilol Approved, Investigational Phase 3 72956-09-3 2585
38
Enalapril Approved, Vet_approved Phase 3 75847-73-3 40466924 5362032
39
Enalaprilat Approved Phase 3 76420-72-9 6917719
40
Acyclovir Approved Phase 3 59277-89-3 2022
41
Tazobactam Approved Phase 3 89786-04-9 123630
42
Vancomycin Approved Phase 3 1404-90-6 14969 441141
43
Piperacillin Approved Phase 3 66258-76-2 43672
44
Dalteparin Approved Phase 3 9005-49-6
45
Tinzaparin Approved Phase 3 9041-08-1, 9005-49-6 25244225
46
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
47
Itraconazole Approved, Investigational Phase 3 84625-61-6 55283
48
Captopril Approved Phase 3 62571-86-2 44093
49
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
50
Ribavirin Approved Phase 3 36791-04-5 37542

Interventional clinical trials:

(show top 50) (show all 1851)
# Name Status NCT ID Phase Drugs
1 Multicenter Study To Optimize Treatment in Elderly Patients (> 55 Years, No Upper Age Limit) With Acute Lymphoblastic Leukemia (GMALL Elderly 1/2003)(Amend 2) Unknown status NCT00198978 Phase 4 Cyclophosphamide;Dexamethasone / Prednisolone;Cytarabine;Idarubicin;Granulocyte-Colony-Stimulating Factor;Mercaptopurine;Methotrexate;Rituximab;HDARAC;Vincristine;Depocyte;Asparaginase
2 German Multicenter Study for Treatment Optimisation in Acute Lymphoblastic Leukemia in Adults and Adolescents Above 15 Years (Amend 3) (GMALL 07/2003) Unknown status NCT00198991 Phase 4 Cyclophosphamide;Dexamethasone;Vincristine;daunorubicin;Asparaginase;Methotrexate;Cytarabine;Mercaptopurine;G-CSF;Vindesine;VP16;Prednisolone;Adriamycin;Thioguanine;VM26;Idarubicin;Fludarabine;Cladribine
3 Philadelphia -Negative High-risk Children Acute Lymphoblastic Leukemia(ALL) Treatment:Induction Therapy:Vincristine(V),Idarubicin(I),L-asparaginase(L),Dexamethasone(D);Consolidation:V+Daunorubicin(D)+L+D, Methotrexate,Cytarabine Unknown status NCT01990807 Phase 4 Idarubicin(IDA)
4 Ma-Spore ALL 2010 Study Unknown status NCT02894645 Phase 4 Prednisolone;Dexamethasone;L-Asparaginase;Vincristine;Methotrexate;Daunorubicin;Doxorubicin;Cyclophosphamide;Cytarabine;6-Mercaptopurine;Thioguanine;Fludarabine;Imatinib
5 Intensification Therapy of Mature B-ALL, Burkitt and Burkitt Like and Other High Grade Non-Hodgkin's Lymphoma in Adults Unknown status NCT00797810 Phase 4 Rituximab
6 PEG-asparaginase During Two Treatment Courses in the Treatment of Childhood Acute Lymphoblastic Leukemia Unknown status NCT00192673 Phase 4 PEG-asparaginase
7 Medical Research Council Working Party on Leukaemia in Children UK National Acute Lymphoblastic Leukaemia (ALL) Trial: UKALL 2003 Unknown status NCT00222612 Phase 4 Standard childhood UK ALL protocol;Intensified treatment including Capizzi maintenance
8 The Combination of Lower Dosage of Chemotherapy With Tyrosine Kinase Inhibitor to Treat Newly Diagnosed ph+ Acute Lymphoblastic Leukemia Patients Unknown status NCT02690922 Phase 4 Dasatinib;prednisone;dexamethasone;methotrexate
9 Clinical Study of GD-2008 ALL Protocol for Childhood Acute Lymphoblastic Leukemia in Guangdong Province Unknown status NCT00846703 Phase 4 6-mercaptopurine, Methotrexate;6-mercaptopurine, Methotrexate, Vincristine, Dexamethasone
10 Plasma Kinetics of Tablet and Liquid Formulations of 6-mercaptopurine in Childhood Acute Lymphoblastic Leukemia. Unknown status NCT01906671 Phase 4 Xaluprine;Puri-Nethol
11 An Open-label,Multi-center,Prospective Study of Idarubicin and Etoposide Intensified Conditioning Regimen Allogeneic Hematopoietic Stem Cell Transplantation for Adult Acute Lymphoblastic Leukemia Unknown status NCT01873807 Phase 4 IDA;CTX;VP-16
12 Multicenter Trial for Treatment Optimization in T-lymphoblastic Lymphoma in Adults and Adolescents Older Than 15 Years (GMALL T-LBL 1/2004) (Amend 1) Completed NCT00199017 Phase 4 Dexamethasone/Prednisolone;Cyclophosphamide;Vincristine;Daunorubicin;Asparaginase;G-CSF;Mercaptopurine;Cytarabine;Methotrexate;VP16;Vindesine;Adriamycin;Thioguanine;HDARAC;Cladribine
13 Multicenter Study to Optimise Therapy of B-ALL, Burkitt's NHL and High-Grade Non-Hodgkin's Lymphoma in Adults (Amend 7) Completed NCT00199082 Phase 4 Adriamycin;Cyclophosphamide;Cytarabine;Dexamethasone/Prednisolone;VP16;Ifosfamide;Methotrexate;G-CSF;Rituximab;Vincristine/Vindesine
14 The Study on the Pharmacokinetics of Pegylated Recombinant Human Granulocyte Stimulating Factor（PEG-rhG-CSF） in Children and Adolescents Completed NCT02953730 Phase 4 PEG-rhG-CSF
15 Pilot Study for Treatment of Elderly Patients (>65 Years) With Acute Lymphoblastic Leukemia Completed NCT00199095 Phase 4 Adriamycin;Cyclophosphamide;Cytarabine;Dexamethasone;Idarubicin;Ifosfamide;Methotrexate;Mercaptopurine;VM26;Vincristine
16 Multicenter Trial for Treatment of Acute Lymphoblastic Leukemia in Adults (05/93) Completed NCT00199069 Phase 4 Asparaginase;Vincristine;Daunorubicin, Adriamycin;Cyclophosphamide;Ifosfamide;Cytarabine;Mitoxantrone;Methotrexate;6-Mercaptopurine;6-Thioguanine;VM26;Dexamethasone / Prednisolone
17 Multicenter Trial for Treatment of Acute Lymphocytic Leukemia in Adults (Pilot Study 06/99) Completed NCT00199056 Phase 4 Dexamethasone / Prednisolone;Cyclophosphamide;Methotrexate;Vincristine / Vindesine;Daunorubicin;Asparaginase;G-CSF;Cytarabine;6-Mercaptopurine;VP16;Adriamycin;Thioguanine;VM26;Idarubicin;Fludarabine;Ifosfamide
18 German Multicenter Trial for Treatment Optimisation in Acute Lymphoblastic Leukemia in Adults and Adolescents Above 15 Years With Rituximab for Improvement of Prognosis in CD20 Positive Standard Risk ALL (Amend 2) Completed NCT00199004 Phase 4 Cyclophosphamide;Dexamethasone / Prednisolone;Vincristine;Daunorubicin;Asparaginase;Methotrexate;Cytarabine;Mercaptopurine;G-CSF;Vindesine;VP16;Adriamycin;Thioguanine;VM26;Rituximab
19 Pulses of Vincristine and Dexamethasone During Maintenance in BFM Protocols for Children With Intermediate-Risk Acute Lymphoblastic Leukemia Completed NCT00411541 Phase 4 vincristine;dexamethasone
20 A Randomized Open-Label Trial of Posaconazole Versus Micafungin for Prophylaxis Against Invasive Fungal Infections During Neutropenia in Patients Undergoing Chemotherapy for Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia or Myelodysplastic Syndrome Completed NCT01200355 Phase 4 micafungin;posaconazole
21 Prospective Study of Rituximab Combined With Chemotherapy for CD20+ Adult Acute Lymphoblastic Leukemia Completed NCT01358253 Phase 4 Cyclophosphamide;Doxorubicin;Vincristine;Dexamethasone;Cytarabine;Methotrexate;Rituximab;6-Mercaptopurine;Prednisone;L-asparaginase
22 Learning Impairments Among Survivors of Childhood Cancer Completed NCT00576472 Phase 4 Methylphenidate
23 Treatment of High Risk Adult Acute Lymphoblastic Leukemia Completed NCT00853008 Phase 4 Vincristine;Daunorubicin;Prednisone;Mitoxantrone;Cytosine Arabinoside;Dexamethasone;Methotrexate (MTX);Cytarabine;ASP;Mercaptopurine;Teniposide;Hydrocortisone
24 LAL-Ph-2000: Treatment of Acute Lymphoblastic Leukemia Chromosome Philadelphia Positive Completed NCT00526305 Phase 4 Vincristine;Daunorubicin;Prednisone;L-Asparaginase;Mitoxantrone;Cytosine Arabinoside;Hydrocortisone;Mercaptopurine;Cyclophosphamide;Dexamethasone
25 LAL-BR/2001: Study Treatment to Low Risk ALL Completed NCT00526175 Phase 4 Prednisone;Vincristine;Daunorubicin;L-Asparaginase;Cyclophosphamide;Methotrexate;Cytosine Arabinoside;Mercaptopurine;VP-16
26 ALL-REZ BFM 2002: Protocol for the Treatment of Children With Relapsed Acute Lymphoblastic Leukemia Completed NCT00114348 Phase 4
27 PETHEMA LAL-RI/96: Treatment for Patients With Standard Risk Acute Lymphoblastic Leukemia Completed NCT00494897 Phase 4 Asparaginase;Cyclophosphamide;Cytarabine;Daunorubicin;Mercaptopurine;Prednisone;Vincristine;Methotrexate
28 LAL-AR-N-2005: Study Treatment for Children High Risk Acute Lymphoblastic Leukemia Completed NCT00526409 Phase 4 Prednisolone;Daunorubicin;Vincristine;L-Asparaginase;Cyclophosphamide;Methotrexate;Cytosine Arabinoside
29 Evaluation of Allogeneic Marrow Transplants Depleted of T-Cells by CD34+ Selection in Patients Undergoing Transplantation With an Unrelated Matched or 1 Antigen Mismatched Donor or a 1 Antigen Mismatched Related Donor Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
30 A Clinical Trial of Decitabine Combined With CODOX-M/IVAC in Relapsed or Refractory T-lymphoblastic Lymphoma Recruiting NCT03558412 Phase 4 Decitabine
31 A PHASE 4, OPEN-LABEL, RANDOMIZED STUDY OF TWO INOTUZUMAB OZOGAMICIN DOSE LEVELS IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA ELIGIBLE FOR HEMATOPOIETIC STEM CELL TRANSPLANTATION AND WHO HAVE RISK FACTOR(S) FOR VENO-OCCLUSIVE DISEASE Recruiting NCT03677596 Phase 4 inotuzumab ozogamicin-dose level 2;Inotuzumab ozogamicin-dose level 1
32 Hematology , Shanghai Jiaotong University Affiliated Shanghai First People's Hospital, Shanghai, China Recruiting NCT02938741 Phase 4 Anti－human Thymoglobulin;Placebo
33 Identification of New Immune Factors Specific of Relapse in Childhood B Lineage Acute Lymphoblastic Leukemia Recruiting NCT02618109 Phase 4
34 G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor: a Prospective, Multicentre, Randomised Controlled Trial Recruiting NCT02933333 Phase 4
35 Allogeneic Stem Cell Transplant for Children and Adolescents With Acute Lymoblastic Leukemia FORUM - Pharmacogenomic Study (add-on Study) Recruiting NCT02670564 Phase 4
36 PROTOCOL FOR THE TREATMENT Acute Lymphoblastic Leukemia With Ph 'NEGATIVE IN ELDERLY PATIENTS (> 55 Years) Recruiting NCT01366898 Phase 4 Dexamethasona, Idarubicine, ARA-C, Methotrexate
37 Treatment Protocol For All Fragile Patients Ph' Negative Over 55 Years Recruiting NCT01358201 Phase 4 vINCRISTINE;Dexamethasone;Methotrexate;Cytosine arabinoside
38 A Study of Efficacy and Safety of Flumatinib Combined With Chemotherapy in the Treatment of Ph Positive Acute Lymphoblastic Leukemia Based on Minimal Residual Disease Monitoring Recruiting NCT04375683 Phase 4 Flumatinib
39 Chemotherapy and Imatinib in Young Adults With Acute Lymphoblastic Leukemia Ph (BCR-ABL) POSITIVE Recruiting NCT01491763 Phase 4 Imatinib
40 Vaccinating Children After Chemotherapy for Acute Lymphoblastic Leukemia: A Canadian Immunization Research Network Study Active, not recruiting NCT02447718 Phase 4
41 Determinants of Mercaptopurine Toxicity in Paediatric Acute Lymphoblastic Enrolling by invitation NCT03920813 Phase 4 Mercaptopurine
42 A Randomized Phase IV Control Trial of Single High Dose Oral Vitamin D3 (Stoss Therapy) in Pediatric Patients Undergoing HSCT to Prevent Vitamin D Deficiency and Insufficiency During Transplant Enrolling by invitation NCT03176849 Phase 4
43 ProphyALL - Pilot Study on Safety of Four Weekly Administrations of 7 mg/kg of Liposomal Amphotericin B (AmBisome®) in Antifungal Primary Prophylaxis Treatment of Elderly Patients With Acute Lymphoblastic Leukemia Undergoing Induction Chemotherapy Within the GMALL-Elderly Protocol Terminated NCT00386997 Phase 4 liposomal amphotericin B (AmBisome®)
44 Phase III Study of Vincristine Sulfate Liposome Or Vincristine Sulfate For Injection Combined Chemotherapy as Initial Induction Regimen In Adults Acute Lymphoblastic Leukemia Unknown status NCT02072785 Phase 3 Vincristine Sulfate Liposome;Vincristine Sulfate
45 A Phase-2 Clinical Study to Determine the Efficacy and Safety of Depocyt (Cytarabine Liposome Injection) for the Treatment of CNS Relapse in Adult Patients With Acute Lymphoblastic Leukemia or Very Aggressive Lymphoma Unknown status NCT00199108 Phase 2, Phase 3 Depocyt;Dexamethasone
46 Evaluation of Benefit and Side Effects of Double Umbilical Cord Blood Units Stem Cell Transplantation in Hematologic Malignancies Unknown status NCT01015742 Phase 2, Phase 3 Stem cell Transplantation
47 Randomized Controlled Trial to Test Efficacy of High-Dose Methotrexate Consolidation Therapy for BCR-ABL-Negative Acute Lymphoblastic Leukemia in Adults Unknown status NCT00131027 Phase 3 Cyclophosphamide;Daunorubicin;Vincristine;Prednisolone;L-asparaginase;Cytarabine;Etoposide;Dexamethasone;Methotrexate;Mercaptopurine;Doxorubicin;Methotrexate
48 Busulfan Plus Cyclophosphamide vs Total Body Irradiation Plus Cyclophosphamide Conditioning Regimen for Standard-risk Acute Lymphocytic Leukemia Undergoing HLA-matched Allogeneic Hematopoietic Stem Cell Transplantation Unknown status NCT02670252 Phase 2, Phase 3 Busulfan (BU);Cyclophosphamide (CY)
49 The Value of Dexamethasone Versus Prednisolone During Induction and Maintenance Therapy of Prolonged Versus Conventional Duration of L-Asparaginase Therapy During Consolidation and Late Intensification, and of Corticosteroid + VCR Pulses During Maintenance in Acute Lymphoblastic Leukemia and Lymphoblastic Non-Hodgkin Lymphoma of Childhood Unknown status NCT00003728 Phase 3 asparaginase;cyclophosphamide;cytarabine;daunorubicin hydrochloride;dexamethasone;doxorubicin hydrochloride;etoposide;leucovorin calcium;mercaptopurine;methotrexate;methylprednisolone;mitoxantrone hydrochloride;prednisolone;therapeutic hydrocortisone;thioguanine;vincristine sulfate;vindesine
50 Allogeneic Stem Cell Transplantation in Children and Adolescents With Acute Lymphoblastic Leukaemia Unknown status NCT01423747 Phase 3 VP16;VP16, ATG;Fludarabine, OKT3, Treosulfan, Thiotepa;VP16, ATG

Search NIH Clinical Center for Lymphoblastic Lymphoma

Inferred drug relations via UMLS 71 / NDF-RT 50 :


ASPARAGINASE
Cyclophosphamide
Idarubicin
Idarubicin Hydrochloride
Ifosfamide
mercaptopurine
pegaspargase
sargramostim

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Lymphoblastic Lymphoma cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Lymphoblastic Lymphoma:
Blood stem cell transplantation for hematological diseases
Hematopoietic stem cells for treatment of hematologic malignancies
Peripheral blood stem cells for treatment of hematologic malignancies
Embryonic/Adult Cultured Cells Related to Lymphoblastic Lymphoma:
Peripheral blood-derived hematopoietic stem cells (family)
Bone marrow-derived hematopoietic stem cells
Sources

Genetic Tests for Lymphoblastic Lymphoma

About this section
Sources

Anatomical Context for Lymphoblastic Lymphoma

About this section

The Foundational Model of Anatomy Ontology organs/tissues related to Lymphoblastic Lymphoma:

19
Primarily Lymph Nodes, Extranodal Sites

MalaCards organs/tissues related to Lymphoblastic Lymphoma:

40
T Cells, B Cells, Bone, Bone Marrow, Myeloid, B Lymphoblasts, Lymph Node
Sources

Publications for Lymphoblastic Lymphoma

About this section

Articles related to Lymphoblastic Lymphoma:

(show top 50) (show all 1993)
# Title Authors PMID Year
1
Diffuse blastoid B-cell lymphoma: a histologically aggressive variant of t(14;18)-negative follicular lymphoma. 61 54
19633642 2009
2
Immunohistochemical evaluation of FLI-1 in acute lymphoblastic lymphoma (ALL): a potential diagnostic pitfall. 61 54
19349856 2009
3
PAX immunoreactivity identifies alveolar rhabdomyosarcoma. 54 61
19145202 2009
4
K-RasG12D-induced T-cell lymphoblastic lymphoma/leukemias harbor Notch1 mutations and are sensitive to gamma-secretase inhibitors. 61 54
18663146 2008
5
Reactivity with TdT in Merkel cell carcinoma: a potential diagnostic pitfall. 61 54
18480005 2008
6
A six-year-old boy with a suspicious thyroid nodule: intrathyroidal thymic tissue. 54 61
18341382 2008
7
TdT expression in Merkel cell carcinoma: potential diagnostic pitfall with blastic hematological malignancies and expanded immunohistochemical analysis. 61 54
17885674 2007
8
CD26, together with cell surface adenosine deaminase, is selectively expressed on ALK-positive, but not on ALK-negative, anaplastic large cell lymphoma and Hodgkin's lymphoma. 61 54
17071493 2006
9
Primary malignant lymphoma of the central nervous system in an immunocompetent child: a case report. 54 61
16217262 2005
10
Methylation status of cyclin-dependent kinase inhibitor genes within the transforming growth factor beta pathway in human T-cell lymphoblastic lymphoma/leukemia. 61 54
15475071 2004
11
[NSE-positive lymphoblastic lymphoma in a boy with cutaneous involvement, giant splenomegaly, and hyper-gamma globulinemia]. 61 54
15678916 2004
12
[Pathologic diagnoses of core needle biopsies of the mediastinum]. 61 54
15132850 2004
13
CD26 expression correlates with a reduced sensitivity to 2'-deoxycoformycin-induced growth inhibition and apoptosis in T-cell leukemia/lymphomas. 54 61
14760072 2004
14
Immunohistochemical expression of the transcription factor DP-1 and its heterodimeric partner E2F-1 in non-Hodgkin lymphoma. 54 61
12607600 2002
15
The 8p11 myeloproliferative syndrome: a distinct clinical entity caused by constitutive activation of FGFR1. 54 61
11919391 2002
16
Peripheral T-cell lymphoma with aberrant expression of CD79a and CD20: a diagnostic pitfall. 61 54
11235901 2001
17
Ewing sarcoma vs lymphoblastic lymphoma. A comparative immunohistochemical study. 54 61
11190795 2001
18
BCL-6 protein is expressed in precursor T-cell lymphoblastic lymphoma and in prenatal and postnatal thymus. 61 54
11133771 2001
19
Therapy-related T cell lymphoblastic lymphoma with t(11;19)(q23;p13) and MLL gene rearrangement. 54 61
10602439 1999
20
Lymphoblastic lymphoma expressing CD56 and TdT. 61 54
9422326 1998
21
MIC2, TdT, bcl-2, and CD34 expression in paraffin-embedded high-grade lymphoma/acute lymphoblastic leukemia distinguishes between distinct clinicopathologic entities. 61 54
9343323 1997
22
An scl gene product lacking the transactivation domain induces bony abnormalities and cooperates with LMO1 to generate T-cell malignancies in transgenic mice. 61 54
9171354 1997
23
Terminal deoxynucleotidyl transferase staining of malignant lymphomas in paraffin sections: a useful method for the diagnosis of lymphoblastic lymphoma. 54 61
9227346 1997
24
Defects of the mismatch repair gene MSH2 are implicated in the development of murine and human lymphoblastic lymphomas and are associated with the aberrant expression of rhombotin-2 (Lmo-2) and Tal-1 (SCL). 61 54
9116269 1997
25
Lymphoblastic lymphoma expressing natural killer cell phenotype with involvement of the mediastinum and nasal cavity. 54 61
9042293 1997
26
Application of rearrangements of T cell receptor gene in the diagnosis of mediastinal T-lymphoblastic lymphoma: a case report. 61 54
9175304 1997
27
A T cell lymphoblastic lymphoma patient with two malignant cell populations carrying different 9p deletions including the p16INK4 and p15INK4B genes: Clinical response to interferon-alpha therapy in one of the subclones. 61 54
8656689 1996
28
Expression pattern of CD45 RA/RO isoformic antigens in T-lineage neoplasms. 61 54
7741140 1995
29
Involvement of CDKN2 (p16INK4A/MTS1) and p15INK4B/MTS2 in human leukemias and lymphomas. 54 61
7882348 1995
30
Terminal deoxynucleotidyl transferase staining of malignant lymphomas in paraffin sections. 54 61
7937725 1994
31
Lineage determination of CD7+ CD5- CD2- and CD7+ CD5+ CD2- lymphoblasts: studies on phenotype, genotype, and gene expression of myeloperoxidase, CD3 epsilon, and CD3 delta. 61 54
7513945 1994
32
Small cell osteosarcoma of bone: an immunohistochemical study with differential diagnostic considerations. 61 54
7503935 1993
33
Human recombination activating gene-1 in leukemia/lymphoma cells: expression depends on stage of lymphoid differentiation defined by phenotype and genotype. 54 61
8391873 1993
34
Emergence of a B-cell lymphoblastic lymphoma in a patient with B-cell chronic lymphocytic leukemia: evidence for the single-cell origin of the two tumors. 54 61
1859892 1991
35
Flow cytometric analysis of terminal deoxynucleotidyl transferase. 61 54
1996546 1991
36
Expression of enolases in T cell tumors and Hodgkin's disease. 61 54
2255187 1990
37
Genuine CD7 expression in acute leukemia and lymphoblastic lymphoma. 54 61
1701841 1990
38
A Case of Preleukemic Chronic Myeloid Leukemia Following Chemotherapy and Autologous Transplantation for T-lymphoblastic Lymphoma. 61
32311856 2020
39
Whole-joint magnetic resonance imaging to assess osteonecrosis in pediatric patients with acute lymphoblastic lymphoma. 61
32472969 2020
40
Pathogenesis of pediatric B-cell acute lymphoblastic leukemia: Molecular pathways and disease treatments. 61
32565969 2020
41
Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Children With Non-Hodgkin Lymphoma. 61
32576784 2020
42
Primary Paraspinal and Spinal Epidural Non-Hodgkin Lymphoma in Childhood. 61
32520843 2020
43
SALL4 is a useful marker for pediatric yolk sac tumors. 61
32222813 2020
44
Outcome of adults with relapsed/refractory T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma. 61
32501545 2020
45
Low level CpG island promoter methylation predicts a poor outcome in adult T-cell acute lymphoblastic leukemia. 61
31537687 2020
46
T-cell blast crisis of chronic myelogenous leukemia presented with coexisting p210 and p190 BCR-ABL transcripts and t(10;11)(q11;p15). 61
32052899 2020
47
LMO2 Expression Distinguishes T-Lymphoblastic Leukemia/Lymphoma from Indolent T-Lymphoblastic Proliferations. 61
32526041 2020
48
Nelarabine-associated myelopathy in a patient with acute lymphoblastic leukaemia: Case report. 61
32517638 2020
49
Haploidentical hematopoietic stem cell transplantation with 'Beijing protocol' in the treatment of T-lymphoblastic lymphoma. 61
32543937 2020
50
Successful Outcomes of Newly Diagnosed T Lymphoblastic Lymphoma: Results From Children's Oncology Group AALL0434. 61
32552472 2020
Sources

Variations for Lymphoblastic Lymphoma

About this section
Sources

Expression for Lymphoblastic Lymphoma

About this section
Search GEO for disease gene expression data for Lymphoblastic Lymphoma.
Sources

Pathways for Lymphoblastic Lymphoma

About this section

Pathways related to Lymphoblastic Lymphoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Transcriptional misregulation in cancer 36
11.72 MYC MPO LMO2 KMT2A FLI1 BCL6
2
NF-kappaB Signaling 4
11.68 TNFRSF8 TAL1 RAG1 PTPRC MPO FLI1
3
Hematopoietic Stem Cells and Lineage-specific Markers 64
11.62 PTPRC NOTCH1 MPO MME CD5
4
Neural Crest Differentiation 1
11.59 NOTCH1 MYC FGFR1
5
Hematopoietic cell lineage 36
11.55 MME DNTT CD7 CD5
6
Validated targets of C-MYC transcriptional repression 1
11.33 MYC DNTT CDKN2B
7
Hematopoietic Stem Cell Differentiation 1
11.18 NOTCH1 LMO2 FLI1
Sources

GO Terms for Lymphoblastic Lymphoma

About this section

Biological processes related to Lymphoblastic Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 regulation of transcription by RNA polymerase II GO:0006357 9.85 ZMYM2 TAL1 NOTCH1 MYC FLI1 BCL6
2 lung development GO:0030324 9.61 NOTCH1 MME FGFR1
3 regulation of cell proliferation GO:0042127 9.56 TAL1 NOTCH1 FGFR1 BCL6
4 B cell differentiation GO:0030183 9.5 RAG1 PTPRC BCL6
5 positive regulation of transcription by RNA polymerase II GO:0045944 9.5 TAL1 NOTCH1 MYC LMO2 KMT2A FLI1
6 megakaryocyte development GO:0035855 9.48 TAL1 FLI1
7 embryonic hemopoiesis GO:0035162 9.46 TAL1 KMT2A
8 generation of neurons GO:0048699 9.4 TAL1 FGFR1
9 regulation of hematopoietic stem cell differentiation GO:1902036 9.33 TAL1 LMO2 KMT2A
10 megakaryocyte differentiation GO:0030219 8.62 TAL1 CDKN2B

Molecular functions related to Lymphoblastic Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.91 ZMYM2 TNFRSF8 TAL1 RAG1 PTPRC NOTCH1
2 DNA-binding transcription factor activity, RNA polymerase II-specific GO:0000981 9.73 ZMYM2 TAL1 MYC LMO2 KMT2A FLI1
3 chromatin binding GO:0003682 9.55 TAL1 NOTCH1 MPO FLI1 BCL6
4 E-box binding GO:0070888 8.8 TAL1 MYC LMO2
Sources

Sources for Lymphoblastic Lymphoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....